.Jill Feldman - breaking information into smaller pieces and sketching things out can help Effective communication is an absolute necessity for patient centred care #WCLC24

Pippa Labuc - need for expanded MDTs with allied health professionals. Need to ensure that you are looking at the person as a person and not as a treatment. #WCLC24

Pippa Labuc - the psychosocial impact of lung cancer needs to be discussed at multi disciplinary meetings #WCLC24

Excellent talk from Pippa Labuc on ways multi disciplinary care can improve outcomes #WCLC24

.Clarissa Mathias a number of the long term effects of treatment can often be overlooked, particularly psychological distress. Financial toxicity is also a huge issue. #WCLC24

It was a privilege to be part of the 'Global aspects of patient care' session at #WCLC24 with Clarissa Mathias Jill Feldman Pippa Labuc Thanks to the co chairs Dr. Amy C. Moore Navneet Singh #WCLC24 📷 Emilie P

Very lovely celebration plenary - celebrating the last 50 years of IASLC. Also great to see the special shout out to STARS ❤️ #WCLC24 #IASLC50

Privileged to be a mentor on the STARS programme with this amazing group of individuals. Huge congratulations to all the 2024 scholars 👏❤️👏 #WCLC24

Making sure to pin #Donegal on the map at #WCLC24 🙂

Dr. Xiuning Le MD PhD presents data on BAY 2927088 in #HER2 mutant NSCLC from the SOHO-01 study at the #WCLC24 Presidential Plenary. Here: results from cohort D with prior therapy but no prior HER2 directed therapy

Congrats! pierre murchan presenting his work on 'Prognostic gene expression profiling in lung adenocarcinoma using deep learning applied to whole slide images' at #WCLC24 👏👏👏 Orla Sheils Pilib Ó Broin Steve Finn

BAY2927088 Xiuning Le MD PhD for HER2 AGA cohort SOHO-01. 70% YMVA. ORR 72.1%. mDoR 8.7mo PFS 7.5mo. 90%ORR in YMVA. 62% ORR in CNS mets. 25% G3 diarrhea (!) V active therapy with nice intra and extracranial activity #WCLC24

#WCLC24 BAY 2927088 in #HER2 NSCLC with RR 71.2%, mDOR 8.7m, mPFS 7.5m.

#WCLC24 In #HER2 YVMA mt NSCLC, RR 90%, DCR 96.7%. Toxicity includes diarrhea in 86.4% including 25% grade 3 diarrhea. 31.8% dose reductions due to TRAEs. No reports of ILD.

Zongertinib BEAMION-Lung01 pretreated HER2 TKD M+. 120Mg dose chosen. 65% YVMA. 1% g3 diarrhea. Low G3+ TRAEs. ORR 72.4%. Intracranial ORR 33% (RANO). Another highly active HER2 TKI. Looking forward to future development #WCLC24

Dr. Gerrina Ruiter presents an update on the Beamion LUNG-1 study: zongertinib in #HER2 mutant NSCLC at the #WCLC24 Presidential Plenary. Here, Phase Ib cohort 1: previously treated NSCLC with a #HER2 TKD mutation that set the dose of 120mg by mouth daily.

#WCLC24 Beamion LUNG-1 cohort 1 includes 132 pts with a median follow up of 13 weeks for efficacy. Most common mutation is the YVMA and ~40% with brain metastases. Diarrhea in 43% but only 1% grade 3 at the 120mg dose. Rash in 24%, ALT elevation in 19% (8% G3), AST 21% (5% G3).

#WCLC24 Zongertinib in previously treated #HER2 mutant NSCLC at the recommended 120mg daily oral dose had a RR of 66.7%, after randomization implemented, RR 72.4% at 120mg (vs 78.2% at 240mg). DCR rate 95-100%. DOR and PFS pending (2/3 of pts still on therapy).

Dr Chee Lee discusses SOHO-01 & BEAMION-Lung01. Questions re how do these stack against T-DxD. Is BAY 20mg BID optimal schedule? Ph3 trials for both underway. #WCLC24

We now have 2 highly active HER TKis and 1 ADC with phase 3 trials ongoing. Pt identification- genomic testing- understanding Resistance mechanisms and sequencing will be key in maximizing efficacy #WCLC24